197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study

Background

This study aimed to investigate characteristics, treatment patterns and clinical outcomes of Chinese patients with UAM GA/GEJA in real-world settings.

Methods

This was a multicenter, retrospective, observational study using electronic medical records from four tertiary hospitals. Adult patients who were diagnosed with UAM GA/GEJA between Jan 1, 2017 and Dec 31, 2020 and had ≥1 inpatient admission related to UAM GA/GEJA from diagnosis to Aug 31, 2021 were included. Descriptive statistics were applied to summarize the data and Kaplan- Meier method was used to describe duration of treatment (DoT) and progression-free survival (PFS) by each line of therapy.

Results

Of the 2,745 eligible patients (median age 62 years, 69.2% male), 97.3% had a diagnosis of GA, 94.0% had stage IV disease, and 43.4% had peritoneum metastasis at diagnosis. Of the 2,745 patients, 1,902 (69.3%) received first-line (1L) therapy. Of the 1,902 patients, 729 (38.3%) subsequently received second-line (2L) therapy and 284 (14.9%) received third-line (3L) therapy. The majority of patients received chemotherapy alone in 1L and 2L settings (84.1% in 1L, 63.6% in 2L, 41.4% in 3L). Targeted therapy-based regimen (13.7% in 1L, 30.3% in 2L, 49.2% in 3L) and immunotherapy-based regimen (3.1% in 1L, 8.7% in 2L, 18.5% in 3L) were used more often in 3L setting. The most frequently used treatment regimen in 1L, 2L, and 3L were fluoropyrimidine (FP) plus platinum (44.5%), FP plus taxanes (16.5%), and anti-angiogenic tyrosine kinase inhibitors alone (18.2%), respectively. Median (95% CI) DoT (4.4 months [4.2, 4.8] in 1L, 3.1 months [2.7, 3.6] in 2L, 2.4 months [2.0, 2.9] in 3L) and PFS (6.5 months [6.1, 6.9] in 1L, 4.2 months [3.7, 4.5] in 2L, 3.2 months [2.8, 3.7] in 3L) decreased progressively with each advancing line of therapy.

Conclusions

Patients treated in 1L and 2L mainly received chemotherapy alone at that time. DoT and PFS were generally short in all lines of therapy, which suggests the need for more effective new treatment options.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Eli Lilly and Company.

Funding

Eli Lilly and Company.

Disclosure

G. Segall, L. Zhou, C. Zhou, M. Khanal: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Eli Lilly and Company. All other authors have declared no conflicts of interest.